Academic successes for CombiGene’s scientific founders
This is an article from Ingenious number four 2019.
Professor Merab Kokaia’s and associate professor David Woldbyes proof-of-concept study has been published in Molecular Therapy: Methods & Clinical Development
On February 19th 2018, Professor Merab Kokaia and associate professor David Woldbye, CombiGene’s scientific founders, presented final data from the preclinical proof-of-concept study for CG01 that was conducted in 2017. The study confirmed that CG01 has clinically relevant anti-seizure effects in the form of fewer and shorter seizures. Following peer review, the study has now been published in Molecular Therapy: Methods & Clinical Development. The study was designed to reflect a probable clinical scenario for treatment of epilepsy in humans. With the aid of magnetic resonance imaging, the hippocampus, i.e., the part of the brain in which the epileptic seizure arose and to which treatment was targeted, was localized. Subsequently, a unilateral focal treatment with CG01 was administered to the epileptic focus. Results of the treatment have been analysed with video EEG (electroencephalography) to observe and measure electrical activity in the brain during a seizure.
A histological analysis (tissue analysis) was also used to find detailed answers with respect to deviations in brain tissue and to determine how CG01 is expressed in the brain.
The results of the study show that CG01 has clinically relevant anti-seizure effects. Epileptic seizures were both fewer and shorter in duration and some of the animals were completely free of seizures after being treated.
The article on the proof-of-concept study is available here:
CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282”
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.